Exploring Corvus Pharmaceuticals, Inc. (CRVS) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on Corvus Pharmaceuticals, Inc. (CRVS) and wondering who's investing and, more importantly, why? As of April 17, 2025, the share price stands at $3.23, a notable increase from $1.41 on April 18, 2024. Institutional investors hold a significant stake, with a total of 38,886,423 shares. Recent activity shows that RTW INVESTMENTS, LP added 2,679,479 shares in Q4 2024, amounting to approximately $14,335,212, while POINT72 ASSET MANAGEMENT, L.P. reduced their holdings by 2,532,718 shares, valued at around $13,550,041.

Corvus Pharmaceuticals, Inc. (CRVS) Who Invests in Corvus Pharmaceuticals, Inc. (CRVS) and Why?

Understanding the investor profile of Corvus Pharmaceuticals, Inc. (CRVS) provides valuable insights into market sentiment and the factors driving investment decisions. Investors are typically categorized into retail investors, institutional investors, and hedge funds, each bringing different motivations and strategies.

Key Investor Types:

A diverse range of investors are involved with Corvus Pharmaceuticals, Inc. (CRVS), each with their unique investment styles and objectives:

• Retail Investors: These individual investors often trade in smaller volumes and may be influenced by news, market trends, and the company's perceived growth potential. Their investment decisions can be driven by both short-term gains and long-term prospects.
• Institutional Investors: This group includes mutual funds, pension funds, insurance companies, and other large entities. These investors typically hold significant stakes in the company and conduct thorough research before investing.
• Hedge Funds: Known for their aggressive investment strategies, hedge funds aim to maximize returns through various techniques, including short-term trading, arbitrage, and leveraging. Their involvement can lead to increased market volatility.

Investment Motivations:

Several factors attract investors to Corvus Pharmaceuticals, Inc. (CRVS):

• Growth Prospects: The biotechnology sector is known for its high-growth potential, particularly for companies developing innovative therapies. Positive clinical trial results and regulatory approvals can significantly boost investor confidence.
• Market Position: Corvus Pharmaceuticals, Inc. (CRVS)'s position in the competitive landscape influences investor decisions. A strong pipeline of drug candidates and strategic partnerships can enhance its market position and attract more investment.

Investment Strategies:

Investors in Corvus Pharmaceuticals, Inc. (CRVS) employ various strategies, depending on their risk tolerance and investment goals:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, focusing on the company's potential for sustained growth and profitability over several years. This approach requires a deep understanding of the company's fundamentals and industry trends.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading, capitalizing on price fluctuations driven by news events, clinical trial updates, and market sentiment. This strategy is riskier but can yield quick profits.
• Value Investing: Some investors may view Corvus Pharmaceuticals, Inc. (CRVS) as undervalued based on its assets, intellectual property, and future earnings potential. They invest with the expectation that the market will eventually recognize the company's true value.

For more in-depth information on the company's background, mission, and ownership structure, you can explore this resource: Corvus Pharmaceuticals, Inc. (CRVS): History, Ownership, Mission, How It Works & Makes Money

Corvus Pharmaceuticals, Inc. (CRVS) Institutional Ownership and Major Shareholders of Corvus Pharmaceuticals, Inc. (CRVS)

The ownership structure of Corvus Pharmaceuticals, Inc. (CRVS) stock is a mix of institutional, retail, and individual investors.

As of a recent analysis:

• Institutional Investors own approximately 4.48% to 8.97% of the company’s stock.
• Insiders own approximately 33.03%.
• Public Companies and Individual Investors own approximately 4.49% to 57.99%.

Peter A. Thompson owns the most shares of Corvus Pharmaceuticals Inc (CRVS).

Here is additional data regarding Corvus Pharmaceuticals, Inc. (CRVS): Corvus Pharmaceuticals, Inc. (CRVS): History, Ownership, Mission, How It Works & Makes Money

Top Institutional Investors

According to SEC filings, Corvus Pharmaceuticals, Inc. (CRVS) has 117 to 119 institutional owners and shareholders. These institutions hold a total of 38,871,423 to 38,886,423 shares.

The largest shareholders include:

• Orbimed Advisors LLC: 6.94M shares as of December 31, 2024, representing 10.19% of outstanding shares.
• Samlyn Capital, LLC: 6.67M shares as of December 31, 2024, representing 9.79% of outstanding shares.
• Adams Street Partners LLC: 3.28M shares as of December 31, 2024, representing 4.81% of outstanding shares.
• Point72 Asset Management, L.P.
• RTW Investments, LP
• Vanguard Group Inc
• Vivo Capital, LLC
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• Foresite Capital Management VI LLC
• BlackRock, Inc.

Changes in Ownership

Recent hedge fund activity shows:

• 53 institutional investors added shares of Corvus Pharmaceuticals stock to their portfolio.
• 22 decreased their positions in their most recent quarter.

Some of the largest recent moves include:

• RTW INVESTMENTS, LP added 2,679,479 shares (+inf%) in Q4 2024, for an estimated $14,335,212.
• SAMLYN CAPITAL, LLC added 2,136,772 shares (+47.2%) in Q4 2024, for an estimated $11,431,730.
• DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 1,000,000 shares (+inf%) in Q4 2024, for an estimated $5,350,000.
• SUSQUEHANNA INTERNATIONAL GROUP, LLP added 796,121 shares (+363.6%) in Q4 2024, for an estimated $4,259,247.
• VIVO CAPITAL, LLC added 737,298 shares (+49.2%) in Q4 2024, for an estimated $3,944,544.
• SPHERA FUNDS MANAGEMENT LTD. added 500,491 shares (+inf%) in Q4 2024, for an estimated $2,677,626.

However, POINT72 ASSET MANAGEMENT, L.P. removed 2,532,718 shares (-45.5%) from their portfolio in Q4 2024, for an estimated $13,550,041.

Impact of Institutional Investors

The ownership structure can significantly impact a company's decision-making. Large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.

As of April 17, 2025, the share price was $3.23 / share, an increase of 129.08% over the share price of $1.41 / share on April 18, 2024.

Wall Street analysts have issued reports on Corvus Pharmaceuticals. Recent analyst ratings include:

• H.C. Wainwright issued a 'Buy' rating on 01/02/2025.
• Jefferies issued a 'Buy' rating on 11/13/2024.

The median price target from analysts is $12.5. Roger Song from Jefferies set a target price of $13.0 on 11/13/2024, and Graig Suvannavejh from Mizuho Securities set a target price of $12.0 on 10/22/2024.

Corvus Pharmaceuticals, Inc. (CRVS) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Corvus Pharmaceuticals, Inc. (CRVS) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining who holds significant stakes in Corvus Pharmaceuticals, Inc. (CRVS) can reveal a lot about the perceived value and future prospects of the company.

While specific, real-time details on all major investors and their recent moves can fluctuate, focusing on the types of investors generally interested in biotech firms like Corvus Pharmaceuticals, Inc. (CRVS) is beneficial. These typically include:

• Institutional Investors: Mutual funds, pension funds, hedge funds, and other large financial institutions often hold substantial shares in publicly traded companies. Their investment decisions are usually based on in-depth research and analysis.
• Venture Capital Firms: Given Corvus Pharmaceuticals, Inc. (CRVS)'s focus on developing novel therapies, venture capital firms that specialize in biotechnology may have an early stake in the company.
• Strategic Partners: Pharmaceutical companies might invest in or partner with Corvus Pharmaceuticals, Inc. (CRVS) to gain access to its innovative drug candidates or technologies.
• Individual Investors: High-net-worth individuals with an interest in the biotech sector may also hold shares.

Investor influence can manifest in several ways:

• Voting Rights: Large shareholders have a greater say in company matters that require shareholder approval, such as board elections, mergers, and significant corporate changes.
• Market Sentiment: Major investments or divestments by prominent investors can impact market sentiment, driving stock price fluctuations.
• Strategic Guidance: Some investors may take an active role in advising the company's management on strategic decisions.

Keeping track of major investor moves, such as large stake acquisitions or sales, can provide clues about the evolving perception of Corvus Pharmaceuticals, Inc. (CRVS)'s prospects. Information on these moves can often be found in SEC filings (e.g., 13D, 13G, Form 4), press releases, and financial news reports.

For more background information, you can explore: Corvus Pharmaceuticals, Inc. (CRVS): History, Ownership, Mission, How It Works & Makes Money

Corvus Pharmaceuticals, Inc. (CRVS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Corvus Pharmaceuticals, Inc. (CRVS) is crucial for current and potential shareholders. Analyzing major shareholders' perspectives, recent market behavior, and analyst insights provides a comprehensive view of the company's stock performance and future outlook.

Investor Sentiment: The sentiment of major shareholders significantly influences a company's stock stability and growth potential. Positive sentiment typically leads to increased investment and stability, while negative sentiment can trigger sell-offs and volatility. Unfortunately, pinpointing the exact current sentiment (positive, neutral, or negative) of major shareholders towards Corvus Pharmaceuticals, Inc. requires real-time data from financial news sources, filings, and sentiment analysis tools, which are constantly updated. However, here are some general factors that could be considered:

• Institutional Ownership: High institutional ownership often indicates confidence in the company's long-term prospects.
• Insider Transactions: Monitoring insider buying and selling can provide insights into how company executives view the stock's value.
• Shareholder Activism: Any activist investors taking positions in CRVS could signal potential changes or strategic shifts being pushed within the company.

Recent Market Reactions: Stock market responses to changes in ownership or large investor moves can be immediate and significant. For Corvus Pharmaceuticals, Inc., these reactions might include:

• Sudden Price Swings: A large institutional investor increasing or decreasing their stake could cause noticeable price fluctuations.
• Trading Volume Changes: Increased trading volume often accompanies significant investor activity, indicating heightened market interest.
• Volatility: Major investor moves can increase the stock's volatility, especially if the news is unexpected or perceived as a major shift in the company's outlook.

Analyst Perspectives: Analysts' opinions on Corvus Pharmaceuticals, Inc. are vital for understanding the potential impact of key investors on the company's future. Analyst perspectives typically consider:

• Stock Ratings and Price Targets: Changes in ratings (buy, sell, hold) and price targets often reflect analysts' views on how investor activity will affect the stock's performance.
• Earnings Estimates: Analysts revise their earnings estimates based on factors like major investments, clinical trial outcomes, and market conditions, all of which can be influenced by key investors.
• Long-Term Growth Prospects: Analysts evaluate how key investors and their strategies might impact the company's long-term growth prospects, considering factors like innovation, market expansion, and competitive positioning.

For a deeper dive into the company's financial standing, explore Breaking Down Corvus Pharmaceuticals, Inc. (CRVS) Financial Health: Key Insights for Investors.

To illustrate how investor sentiment and market reactions can play out, consider the following hypothetical scenarios:

Keeping abreast of real-time financial news, SEC filings, and analyst reports is essential for staying informed about the evolving investor landscape surrounding Corvus Pharmaceuticals, Inc.